Ignite Creation Date:
2025-12-24 @ 6:52 PM
Ignite Modification Date:
2026-01-25 @ 7:34 AM
Study NCT ID:
NCT01748357
Status:
COMPLETED
Last Update Posted:
2014-11-06
First Post:
2012-12-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Siemens VOC TB Pilot Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014376', 'term': 'Tuberculosis'}], 'ancestors': [{'id': 'D009164', 'term': 'Mycobacterium Infections'}, {'id': 'D000193', 'term': 'Actinomycetales Infections'}, {'id': 'D016908', 'term': 'Gram-Positive Bacterial Infections'}, {'id': 'D001424', 'term': 'Bacterial Infections'}, {'id': 'D001423', 'term': 'Bacterial Infections and Mycoses'}, {'id': 'D007239', 'term': 'Infections'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Volatile compounds from exhaled breath'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 60}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-11', 'completionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-11-05', 'studyFirstSubmitDate': '2012-12-07', 'studyFirstSubmitQcDate': '2012-12-11', 'lastUpdatePostDateStruct': {'date': '2014-11-06', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-12-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of correctly identified patients with tuberculosis', 'timeFrame': 'Day of admission to hospital', 'description': 'The VOC pattern is used to differentiate tuberculosis patients from patients with non-tuberculosis inflammatory lung disease and from healthy volunteers'}], 'secondaryOutcomes': [{'measure': 'Change in VOC pattern induced by storage for several days', 'timeFrame': 'At days 3, 5 and 7 after sample collection'}, {'measure': 'Change in VOC pattern induced by storage temperature', 'timeFrame': 'At days 3, 5 and 7 after sample collection'}, {'measure': 'Change in VOC pattern induced by tuberculosis therapy', 'timeFrame': 'After completion of recruitment'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Tuberculosis', 'Volatile organic compounds', 'exhaled breath', 'Siemens'], 'conditions': ['Tuberculosis']}, 'descriptionModule': {'briefSummary': 'Tuberculosis is a bacterial infection causing 1.1 million deaths annually worldwide. Diagnosis of the disease is often time consuming or challenging. Many cases of tuberculosis require advanced and expensive diagnostic methods that restrict their availability in resource limited countries where the burden of tuberculosis is highest. The development of rapid point of care diagnostics is required.\n\nPublished data confirm that trained African giant-pouched rats are able to identify M. tuberculosis cultures through olfactory recognition. A first trial using an electronic nose reported a rate of detection of 85% in tuberculosis patients. A further trial was closed in June 2011 but remains unpublished, yet. The olfactory pattern that potentially allows the recognition of tuberculosis remains unknown.\n\nThis trial aims to detect first patterns of volatile organic compounds (VOCs) that bear a potential for further development and fine tuning. A technical prototypic device of Siemens is used for pattern detection.\n\nThe study is comparing 3 groups of patients:\n\n* patients with confirmed active pulmonary tuberculosis (n=20)\n* patients with other inflammatory lung diseases (pneumonia, sarcoidosis, COPD, bronchial carcinoma) (n=20)\n* healthy volunteers that do not work in the hospital or visit the hospital regularly Detailed data for all study subjects will be collected for this trial in order to eliminate confounding factors. Furthermore, detailed data of the surroundings of the patient, the surroundings of the technical device and of the operator will be captured.\n\nHypothesis:\n\nThe pattern of exhaled volatile organic compounds allows the detection of pulmonary tuberculosis'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'See groups described above', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Confirmed pulmonary infection with M. tuberculosis (MTB) or other inflammatory disease of the lower respiratory tract (i.e. pneumonia, sarcoid, bronchial carcinoma) or healthy subject that is not employed or working at the study site\n2. Oral and written consent to study participation\n\nExclusion Criteria:\n\n1. Tuberculosis therapy \\>1 week\n2. Inability to follow the study requirements\n3. Patient in custodianship or guardianship\n4. Other lung diseases that are not listed in the inclusion criteria.'}, 'identificationModule': {'nctId': 'NCT01748357', 'briefTitle': 'Siemens VOC TB Pilot Study', 'organization': {'class': 'OTHER', 'fullName': 'Research Center Borstel'}, 'officialTitle': 'Pattern Recognition of Volatile Organic Compounds (VOC) in Exhaled Breath for the Diagnosis of Pulmonary Tuberculosis', 'orgStudyIdInfo': {'id': 'RCBorstel003'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Tuberculosis group', 'description': 'Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis \\>1 week are excluded.'}, {'label': 'Inflammation group', 'description': 'Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.'}, {'label': 'Healthy group', 'description': 'Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '23845', 'city': 'Borstel', 'state': 'Schleswig-Holstein', 'country': 'Germany', 'facility': 'Research Center Borstel', 'geoPoint': {'lat': 53.81586, 'lon': 10.20407}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Research Center Borstel', 'class': 'OTHER'}, 'collaborators': [{'name': 'Siemens Corporate Technologies', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Head of Center for Clinical Trials', 'investigatorFullName': 'Christian Herzmann', 'investigatorAffiliation': 'Research Center Borstel'}}}}